Company
Overview
Our primary mission is to create new medical technologies and businesses
which improve the lives of patients and create value for our customers
and shareholders.
Founded in 1995, ExploraMed is a venture-backed
medical technology incubation company dedicated to the identification,
creation and development of new medical device businesses. ExploraMed
provides expertise, intellectual property and capital to new ideas
which match certain key fundamental criteria and focuses on developing
these opportunities in an efficient and timely manner.
Partnered
with New Enterprise Associates and several key business and clinical
leaders from the medical technology industry, ExploraMed has the
capability to leverage substantial financial and intellectual resources
to accelerate the creation and establishment of new medical technologies,
procedures and companies.
ExploraMed I created two medical
device companies, EndoMatrix
Inc.,
and TransVascular
Inc. EndoMatrix was created to develop a novel
approach towards tissue bulking in incontinence and GI Reflux, and
was acquired by C.R.
Bard, Inc. in
1997. TransVascular, Inc. was created to develop several novel revascularization
technologies including percutaneous coronary and peripheral bypass
and cell injection technologies for cardiac regeneration, and was
acquired by Medtronic,
Inc. in 2003.
ExploraMed II, founded
in 2004, was slated to create two to three new companies and has
thus far produced two new businesses, Acclarent
Inc.. and NeoTract
Inc. . Acclarent,
Inc., a company focused on developing several new technologies in
the field of ENT, exited the incubator in January 2005. Acclarent,
Inc. is currently commercializing their technology and has received
over $42MM in venture funding from Versant
Ventures,
NEA and others. NeoTract, Inc., ExploraMed’s most recent
spinout, exited ExploraMed II in February 2006 and raising over $13MM
in venture funding from NEA and others.
ExploraMed III was launched in 2006 and has already spun off it's first company, Vibrynt, Inc. ExploraMed III expects to create one or two more companies over the next three years.
|